CPI

Thailand’s Anti-Corruption Commission initiates an Anti-Corruption Education curriculum to educate Thai children and instill integrity value in society

Retrieved on: 
Wednesday, April 10, 2024

Corruption in Thai society during the past period has had enormous negative effects on the country and is a major obstacle to the country's development in all dimensions.

Key Points: 
  • Corruption in Thai society during the past period has had enormous negative effects on the country and is a major obstacle to the country's development in all dimensions.
  • However, nowadays it has changed to become more complex which is involved with a conflict of interest and policy corruption.
  • "Children and youth are the future and hope of the country we can instill the idea that corruption is an unusual thing in society.
  • All of those are considered challenging goals of the NACC in driving the anti-corruption education curriculum toward future achievement.

EQS-News: CPI PROPERTY GROUP – Stefano Filippi Appointed Head of Corporate Finance

Retrieved on: 
Wednesday, April 10, 2024

CPI PROPERTY GROUP (“CPIPG”) is pleased to announce the appointment of Stefano Filippi as Head of Corporate Finance.

Key Points: 
  • CPI PROPERTY GROUP (“CPIPG”) is pleased to announce the appointment of Stefano Filippi as Head of Corporate Finance.
  • Stefano is a graduate of University Luigi Bocconi and conducted postgraduate studies at London Business School and King's College London – Dickson Poon School of Law.
  • “Attracting top talent typically leads to the best results, and we look forward to seeing Stefano in action.”’
    In addition to his group corporate finance responsibilities, Stefano will also assume the role of country manager for Italy.
  • Giuseppe Colombo, who served in that role with distinction for nearly five years, will remain with CPIPG as Senior Advisor for Italy.

EQS-News: CPI PROPERTY GROUP publishes financial results for 2023

Retrieved on: 
Wednesday, April 10, 2024

CPI PROPERTY GROUP (hereinafter “CPIPG”, the “Company” or together with its subsidiaries the “Group”), a leading European landlord, hereby publishes audited financial results for the financial year ended 31 December 2023.

Key Points: 
  • CPI PROPERTY GROUP (hereinafter “CPIPG”, the “Company” or together with its subsidiaries the “Group”), a leading European landlord, hereby publishes audited financial results for the financial year ended 31 December 2023.
  • “CPIPG’s results in 2023 demonstrate the resilient and high-yielding nature of real estate in the CEE region,” said David Greenbaum, CEO.
  • The Group raised over €2.5 billion of secured and unsecured external financing in 2023, including €1.2 billion of fresh cash.
  • CPIPG will host a webcast in relation to its financial results for 2023.

The National Anti-Corruption Commission Thailand joins forces with international agencies to focus on preventing and suppressing transnational corruption

Retrieved on: 
Wednesday, April 10, 2024

BANGKOK, THAILAND - Media OutReach Newswire - 25 March 2024 - As emerging with rapid digitalization that paves the way for transnational corruption, the National Anti-Corruption Commission (NACC), Thailand further tightened its collaboration with international organizations in tackling new tactics and complicated illicit activities in accordance with global standards. The NACC's Secretary-General, Mr. Niwatchai Kasemmongkol recently met with representatives of the Nordic Police Liaison Office, led by Mr. Carsten Andersen, Assistant Attache/Liaison Officer, Nordic Police Affairs Department at the Danish Embassy, Thailand and Ms. Jane Ohlsson, Assistant Ambassador/Coordinating Officer for Police Affairs in the Nordic Countries at the Swedish Embassy, Thailand, along with NACC's executives and representatives from the Bureau of International Corruption Affairs and Cases, and the Bureau of Investigation and Special Affairs to enhance cooperation between the NACC enforcement agencies in combating transnational corruption. "Current corruption problems are not limited to any one country. But it has developed into a transnational crime, which affects all countries around the world. Therefore, cooperation between each other in various forms, both bilateral and multilateral is considered an important mechanism for effectively preventing transnational corruption of all kinds," said the NACC secretary-general. He further elaborated that the NACC has collaboration with enforcement agencies from the Nordic countries in both bilateral and multilateral. It has a memorandum of understanding between each other to exchange legal information, coordinate cases, as well as academic cooperation in particular, the sharing of knowledge and anti-corruption practices which is beneficial to raising the level of the Corruption Perceptions Index (CPI) of Thailand. This tie collaboration will help promote the prevention and suppression of corruption in Thailand more effectively. Furthermore, under the cooperation, both sides discussed and exchanged information on international cooperation in criminal matters related to corruption cases between Thailand and the Nordic countries. Denmark has expressed great interest in the NACC's corruption prosecutions and is willing to cooperate in solving transnational corruption cases, while also exchanging information that is beneficial to the fight against corruption. Mr. Niwatchai concluded that the NACC has given great importance to strengthening and expanding the network of cooperation with law enforcement agencies of various countries to deal with transnational corruption continuously. Presently, the NACC, in Thailand has made memoranda of understanding with 25 law enforcement agencies and international organizations, including nine ASEAN countries, the Ministry of Supervision of China, the Independent Authority against Corruption of Mongolia, the Anti-Corruption Commission of Bhutan, the Independent Commission Against Corruption of Australia, the Oversight and Anti-Corruption Authority of Saudi Arabia, the Police Presidium of the Czech Republic, Federal Ministry of the Interior of Austria, Investigative Committee of the Russian Federation, International Department of the National Crime Agency of the United Kingdom, and Office of the Comptroller General of Brazil, as well as World Bank, United Nations Office on Drugs and Crime (UNODC), International Anti-Corruption Academy (IACA), Basel Institute on Governance, United Nations Development Programme (UNDP) and the UN International Organization for Migration (IOM). ----------------------------------------- *This exclusive interview translation is funded by the National Anti-Corruption Fund (NACF). Hashtag: #IntegrityWay #AntiCorruption #ZeroCorruption #NACC #NACF

Key Points: 
  • Therefore, cooperation between each other in various forms, both bilateral and multilateral is considered an important mechanism for effectively preventing transnational corruption of all kinds," said the NACC secretary-general.
  • He further elaborated that the NACC has collaboration with enforcement agencies from the Nordic countries in both bilateral and multilateral.
  • Furthermore, under the cooperation, both sides discussed and exchanged information on international cooperation in criminal matters related to corruption cases between Thailand and the Nordic countries.
  • The National Anti-Corruption Commission (NACC) is a constitutional independent organization and supervised by nine commissioners selected from various professions.

Thor Equities Group Chairman, Joe Sitt, Makes Guest Appearance on Bloomberg Markets to Discuss Inflation, Electric Vehicles, and More

Retrieved on: 
Tuesday, April 9, 2024

On Bloomberg Markets, Joe Sitt was asked about the competition among luxury retailers for properties, which he believes “tend to move cyclically with their stock prices and businesses”.

Key Points: 
  • On Bloomberg Markets, Joe Sitt was asked about the competition among luxury retailers for properties, which he believes “tend to move cyclically with their stock prices and businesses”.
  • Finally, and most remarkably, Joe Sitt discussed electric vehicles, range anxiety, and the Electreon stock which increased 400% since he first mentioned the company on Bloomberg Markets one year prior.
  • Governments across the world are prioritizing electric roads and the company won government issued tenders for electric roads in France, Sweden, Germany, Israel, Norway and China.
  • Thor became interested in the company due to the real estate aspect of parking lots and the solution to difficulties of individual recharging.

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

Retrieved on: 
Tuesday, April 9, 2024

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) --  RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced safety and efficacy data from its ongoing Phase 2 trial of tivumecirnon in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab in the cohort of patients with advanced head and neck squamous cell carcinoma (HNSCC) whose disease progressed despite previous treatment with CPI therapy (CPI-experienced). The results were presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.

Key Points: 
  • The results were presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.
  • The AACR poster highlighted data from the 32-patient CPI-experienced HNSCC cohort in the trial evaluating tivumecirnon, an oral small molecule CCR4 antagonist designed to block the migration of regulatory T cells, in combination with pembrolizumab.
  • Patients in this cohort had heavily pretreated disease, with 69% of patients having received three or more (up to six) prior lines of treatment.
  • In the entire cohort, confirmed responses were observed in 5/32 patients (15.6%) regardless of PD-L1 or HPV status.

BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR

Retrieved on: 
Tuesday, April 9, 2024

“ADCs are the latest treatments for very difficult-to-treat advanced metastatic breast cancer.

Key Points: 
  • “ADCs are the latest treatments for very difficult-to-treat advanced metastatic breast cancer.
  • To our knowledge, there are no effective treatment options in this patient population for whom the progression-free survival prognosis is only a few weeks.
  • BriaCell will be monitoring ADC resistant patients in its ongoing pivotal Phase 3 study of Bria-IMT™ and CPI in advanced metastatic breast cancer.
  • Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study.

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024

Immune responses were generated toward the MHC-I negative tumors by combining CTX-009 with CTX-471.

Key Points: 
  • Immune responses were generated toward the MHC-I negative tumors by combining CTX-009 with CTX-471.
  • The proposed mechanism for this effect suggests the involvement of NK-cells, which can generate potent cell killing independent of MHC-I.
  • Following mCTX-009 and mCTX-471 combination treatment, superior efficacy was observed in MHC Class I negative tumors.
  • A copy of the presentation materials can be accessed on the News & Events section under “ Presentations ” of the Company’s website at www.compasstherapeutics.com once the presentation has concluded.

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

Retrieved on: 
Monday, April 8, 2024

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today at the American Association for Cancer Research (AACR) in San Diego, CA an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, an anti-VISTA monoclonal antibody, as monotherapy and in combination with Merck’s anti-PD1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors.

Key Points: 
  • KVA12123 cleared the fifth of six monotherapy dose levels and the second of four cohorts in combination with pembrolizumab.
  • KVA12123 was well tolerated with no dose limiting toxicities (DLT) or cytokine related adverse events at any dose level.
  • Patients currently enrolled in the trial will be permitted to continue to participate.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

Retrieved on: 
Monday, April 8, 2024

BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, today reported fourth quarter and full year 2023 financial results.

Key Points: 
  • BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, today reported fourth quarter and full year 2023 financial results.
  • The increase was due to revenue earned from our strategic collaboration agreement entered into with Ono Pharmaceutical in the first quarter of 2023.
  • As of December 31, 2023, the Company had approximately $48.5 million in cash, cash equivalents and marketable securities compared with $76.3 million as of December 31, 2022.
  • We expect our current cash, cash equivalents, and marketable securities to fund operations into the first quarter of 2025.